Categories Earnings, Health Care

AbbVie’s Q4 results beat expectations

AbbVie (NYSE: ABBV) topped revenue and earnings expectations for the fourth quarter of 2019, allowing the stock to gain over 3% in premarket hours on Friday.

Net revenues of $8.70 billion was up 4.8% compared to the same period a year ago and ahead of consensus estimates of $8.69 billion. On an operational basis, revenues grew 5.3%.

AbbVie tops Q4 2019 revenue and earnings estimates

HUMIRA revenues in international markets were negatively impacted by biosimilar competition during the quarter and absent this impact, net revenues rose 11% operationally.

On a GAAP basis, the company reported net earnings of $2.8 billion, or $1.88 per share, compared to a net loss of $1.8 billion, or $1.23 per share, last year. Adjusted EPS totaled $2.21, beating forecasts of $2.19.   

Global HUMIRA revenues remained unchanged from the prior-year period. HUMIRA revenues increased 9.8% in the US but declined 27.3% internationally due to biosimilar competition. IMBRUVICA revenues improved almost 29% while revenues from the hematologic oncology portfolio grew 37%.

Also read: AbbVie Q4 2019 Earnings Preview

For the full year of 2020, the company expects GAAP EPS to be $7.66-7.76, representing growth of 46% at the midpoint. Adjusted EPS is estimated to be $9.61-9.71, reflecting growth of 8.1% at the midpoint. Revenue is expected to grow at least 8% operationally.  

AbbVie and Allergan have agreed to divest brazikumab and Zenpep as part of the regulatory approval process related to their proposed acquisition agreement. Brazikumab will be acquired by AstraZeneca while Nestle will take over Zenpep. The divestitures are subject to various approvals and closing conditions. Abbvie expects to complete the acquisition of Allergan in the first quarter of 2020.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

What to look for when CVS Health (CVS) reports Q3 earnings

Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain

eBay (EBAY): A few factors that helped drive growth in Q3 2024

Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,

CVX Earnings: Chevron reports lower revenue and profit for Q3 2024

Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top